RECIST and EASL 腫瘤評(píng)價(jià)標(biāo)準(zhǔn)
《RECIST and EASL 腫瘤評(píng)價(jià)標(biāo)準(zhǔn)》由會(huì)員分享,可在線閱讀,更多相關(guān)《RECIST and EASL 腫瘤評(píng)價(jià)標(biāo)準(zhǔn)(2頁(yè)珍藏版)》請(qǐng)?jiān)谘b配圖網(wǎng)上搜索。
1、RECIST Criteria Measurement and identification of target lesions Patients? must? have? at? least one measurable lesion, defined as a longest diameter >10mm (the slice thickness and/or algorithm must be appropriate to allow? for? measurement of lesions down to 10mm in longest diameter). Where diseas
2、e?is? restricted to a solitary lesion, its neoplastic nature must be confirmed by cytology/histology. Hepatic?target?lesions?should?be?selected?on the basis of lesions for treatment. Baseline?measurements must be taken no more than 2 weeks prior to commencement of treatment.? The same measurement t
3、echnique (CT/MRI) must be?used at baseline and follow up.? Whenever possible, the same individual scanner should be used throughout the study.? No more than 5 target lesions may?be identified in the liver. Those with the largest diameters should be included.? All?other?(non-target)?lesions?should?be
4、?reported?but not measured,?in?order?that their presence of lack thereof may be tracked at follow up. Criteria for target lesions Complete? response:?????? disappearance? of? all? target? lesions? (note: ????????????????????????? elevated tumor markers at baseline must return to ????????????????
5、????????? normal? levels? for a patient to be considered in ????????????????????????? complete clinical response when all tumor lesions ????????????????????????? have disappeared) Partial? response:??????? at least 30% decrease in the sum of the longest ?????????????????? ???????diameter? of? ta
6、rget lesions, taking as reference ????????????????????????? the baseline sum of longest diameter Progressive? disease:???? at least 20% increase in the sum of the longest ????????????????????????? diameter? of? target lesions, taking as reference ????????????????????????? the? smallest sum longe
7、st diameter recorded since ????????????????????????? start? of? treatment OR appearance of one or more ????????????????????????? new lesions Stable? disease:????????? neither? sufficient? shrinkage? to? qualify for ????????????????????????? partial?? response? nor? sufficient? increase? to ????
8、????????????????????? qualify?? for?? progressive? disease,? taking? as ????????????????????????? reference the smallest sum longest diameter since ????????????????????????? start of treatment Criteria for non-target lesions Complete? response:???????? the disappearance of all non target lesions
9、 AND ????????????????????????? normalization of tumor marker level Incomplete? response/stable? disease: persistence of one or more non-target ????????????????????????? lesions? AND/OR maintenance of tumor marker level ????????????????????????? above normal limits Progressive? disease:?????? ap
10、pearance? of? one? or more new lesions AND/OR ????????????????????????? unequivocal? progression? of? existing non-target ????????????????????????? lesions? (progression? of non-target lesions will ????????????????????????? be determined at the investigator’s discretion) Response evaluation and
11、reporting Table 4???? Overall Response??????????????????????????????? ?????????????????????????????????????????? ?? Target??????? |? Non-target?????? |? New Lesions??? |? Overall???????? ?? Lesions?????? |? Lesions????????? |???????????????? |? Response??????? ?----------------+---------------
12、----+-----------------+----------------- ?? CR??????????? |? CR?????????????? |? No???????????? |? CR*???????????? ?----------------+-------------------+-----------------+----------------- ?? CR??????????? |? Incomplete ??????|? No???????????? |? PR????????????? ???????????????? |? response/
13、SD????? |???????????????? |????????????????? ?----------------+-------------------+-----------------+----------------- ?? PR??????????? |? Non-PD?????????? |? No???????????? |? PR? ???????????? ?----------------+-------------------+-----------------+----------------- ?? SD??????????? |? Non-P
14、D?????????? |? No???????????? |? SD????????????? ?----------------+-------------------+-----------------+----------------- ?? PD??????????? |? Any????????????? |? Yes or no????? |? PD????????????? ?----------------+-------------------+-----------------+----------------- ?? Any?????????? |? P
15、D?????????????? |? Yes or no????? |? PD????????????? ?----------------+-------------------+-----------------+----------------- ?? Any?????????? |? Any????????????? |? Yes????????? ?? |? PD????????????? ????????????????????????????????????????????????????????? EASL Tumor Response Evaluation Cri
16、teria The?assessment?of?tumor response using RECIST does not take into account the extent of tumor necrosis that occurs following loco-regional treatment. Extensive?tumor?necrosis?might?not?be paralleled by a reduction in the diameter of the tumor. In 2000, therefore, the European Association for t
17、he Study?of? the? Liver (EASL) recommended a modification to the WHO criteria for use in HCC (Bruix et al 2001). The?EASL Consensus Conference proposed that a reduction in viable tumor is more?appropriate.?? The? use? of? the? EASL criteria (see Table xx) is now accepted? in? assessment? of? treatm
18、ent? response? in? HCC, particularly so following? the? use? of? loco-regional therapies such as chemoembolization; however, a formal guideline for measurement is not currently available. Local?tumor?response?will be measured as progression of treated lesions. New?tumor?development?in? a? previousl
19、y untreated area and extra-hepatic disease will not be considered progression. Table EASL tumor response evaluation of target lesions ?? CR (complete????? |? Complete disappearance of all viable tumors ?? response)???????? |? (target lesions) and no new lesions, determined??? ?????????????????
20、??? |? by two observations not less than 4 weeks apart.?? ?--------------------+---------------------------------------------------- ?? PR (partial?????? |? >50%? reduction in total viable tumor load of all? ?? response)???????? |? measurable??? lesions,??? determined??? by??? two? ?????????
21、??????????? |? observations not less than 4 weeks apart.????????? ?--------------------+---------------------------------------------------- ?? OR (objective???? |? The sum of CR and PR.????????????????????????????? ?? response)???????? |???????????????????????????????????????????????????? ?
22、--------------------+---------------------------------------------------- ?? PD (progressive?? |? At least a 25% increase in size of one or more???? ?? disease)????????? |? target lesions, or the appearance of new lesions.? ?--------------------+---------------------------------------------------- ?? SD (stable??????? |? Any cases that do not qualify for complete???????? ?? disease)????????? |? response, partial response or progressive????????? ???????????????????? |? disease.????????????????????
- 溫馨提示:
1: 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
2: 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
3.本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
5. 裝配圖網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)6整理和復(fù)習(xí)2圖形與幾何第7課時(shí)圖形的位置練習(xí)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)6整理和復(fù)習(xí)2圖形與幾何第1課時(shí)圖形的認(rèn)識(shí)與測(cè)量1平面圖形的認(rèn)識(shí)練習(xí)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)6整理和復(fù)習(xí)1數(shù)與代數(shù)第10課時(shí)比和比例2作業(yè)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)4比例1比例的意義和基本性質(zhì)第3課時(shí)解比例練習(xí)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)3圓柱與圓錐1圓柱第7課時(shí)圓柱的體積3作業(yè)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)3圓柱與圓錐1圓柱第1節(jié)圓柱的認(rèn)識(shí)作業(yè)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)2百分?jǐn)?shù)(二)第1節(jié)折扣和成數(shù)作業(yè)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)1負(fù)數(shù)第1課時(shí)負(fù)數(shù)的初步認(rèn)識(shí)作業(yè)課件新人教版
- 2023年六年級(jí)數(shù)學(xué)上冊(cè)期末復(fù)習(xí)考前模擬期末模擬訓(xùn)練二作業(yè)課件蘇教版
- 2023年六年級(jí)數(shù)學(xué)上冊(cè)期末豐收?qǐng)@作業(yè)課件蘇教版
- 2023年六年級(jí)數(shù)學(xué)上冊(cè)易錯(cuò)清單十二課件新人教版
- 標(biāo)準(zhǔn)工時(shí)講義
- 2021年一年級(jí)語(yǔ)文上冊(cè)第六單元知識(shí)要點(diǎn)習(xí)題課件新人教版
- 2022春一年級(jí)語(yǔ)文下冊(cè)課文5識(shí)字測(cè)評(píng)習(xí)題課件新人教版
- 2023年六年級(jí)數(shù)學(xué)下冊(cè)6整理和復(fù)習(xí)4數(shù)學(xué)思考第1課時(shí)數(shù)學(xué)思考1練習(xí)課件新人教版